Lipella Pharmaceuticals I... (LIPO)
2.55
-0.01 (-0.39%)
At close: Mar 25, 2025, 3:59 PM
-0.39% (1D)
| Bid | 2.7 |
| Market Cap | 6.5M |
| Revenue (ttm) | 311.51M |
| Net Income (ttm) | -2.14B |
| EPS (ttm) | -4.29 |
| PE Ratio (ttm) | -0.59 |
| Forward PE | -0.84 |
| Analyst | Buy |
| Ask | 2.91 |
| Volume | 21,685 |
| Avg. Volume (20D) | 2,293,625 |
| Open | 2.55 |
| Previous Close | 2.56 |
| Day's Range | 2.50 - 2.58 |
| 52-Week Range | 2.02 - 12.00 |
| Beta | 0.15 |
About LIPO
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Th...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2022
Employees 5
Stock Exchange NASDAQ
Ticker Symbol LIPO
Website https://www.lipella.com
Analyst Forecast
According to 1 analyst ratings, the average rating for LIPO stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 527.45% from the latest price.
Stock Forecasts1 month ago
+41.64%
Lipella Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
1 month ago
+80.23%
Lipella Pharmaceuticals shares are trading higher after the company received FDA approval for an expanded access program for LP-310 in oral lichen planus.
